Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nesrina Imami

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Pharmacogenomics|March 30, 2007
Recent HIV-1 infection in a high-risk Ugandan cohort: implications for Phase IIB test-of-concept HIV vaccine trialsAnthony Kebba, Nesrina Imami, Daniel Bugembe-Lule, et al.
AIDS (London, England)|February 25, 2003
Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapyAnn K Sullivan, Gareth A Hardy, Mark R Nelson, et al.
AIDS (London, England)|June 5, 2007
Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patientsGuglielmo Rosignoli, Alison Cranage, Catherine Burton, et al.
Frontiers in Immunology|October 3, 2017
Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune ActivationNishel Mohan Shah, Anna A Herasimtschuk, Adriano Boasso, et al.
Frontiers in Immunology|July 14, 2017
Enrichment of HLA Types and Single-Nucleotide Polymorphism Associated With Non-progression in a Strictly Defined Cohort of HIV-1 ControllersSamantha J Westrop, Alexander T H Cocker, Adriano Boasso, et al.
Oncoimmunology|September 19, 2017
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot studySalvinia Mletzko, David J Pinato, Rebecca C Robey, et al.
AIDS (London, England)|December 4, 2004
Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responsesGareth A D Hardy, Nesrina Imami, Ann K Sullivan, et al.
Antiviral Therapy|August 3, 2007
Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 diseaseAssia Samri, Ruth Goodall, Catherine Burton, et al.
Journal of Leukocyte Biology|April 1, 2005
Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjectsAnthony Kebba, Justin Stebbing, Samantha Rowland, et al.
Vaccine|May 6, 2008
Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunizationLindvi Gudmundsdotter, Ann-Charlotte Boström, Catherine Burton, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Pharmacogenomics|March 30, 2007
Recent HIV-1 infection in a high-risk Ugandan cohort: implications for Phase IIB test-of-concept HIV vaccine trialsAnthony Kebba, Nesrina Imami, Daniel Bugembe-Lule, et al.
AIDS (London, England)|February 25, 2003
Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapyAnn K Sullivan, Gareth A Hardy, Mark R Nelson, et al.
AIDS (London, England)|June 5, 2007
Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patientsGuglielmo Rosignoli, Alison Cranage, Catherine Burton, et al.
Frontiers in Immunology|October 3, 2017
Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune ActivationNishel Mohan Shah, Anna A Herasimtschuk, Adriano Boasso, et al.
Frontiers in Immunology|July 14, 2017
Enrichment of HLA Types and Single-Nucleotide Polymorphism Associated With Non-progression in a Strictly Defined Cohort of HIV-1 ControllersSamantha J Westrop, Alexander T H Cocker, Adriano Boasso, et al.
Oncoimmunology|September 19, 2017
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot studySalvinia Mletzko, David J Pinato, Rebecca C Robey, et al.
AIDS (London, England)|December 4, 2004
Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responsesGareth A D Hardy, Nesrina Imami, Ann K Sullivan, et al.
Antiviral Therapy|August 3, 2007
Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 diseaseAssia Samri, Ruth Goodall, Catherine Burton, et al.
Journal of Leukocyte Biology|April 1, 2005
Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjectsAnthony Kebba, Justin Stebbing, Samantha Rowland, et al.
Vaccine|May 6, 2008
Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunizationLindvi Gudmundsdotter, Ann-Charlotte Boström, Catherine Burton, et al.
Pageof 6